Scholars Central

Conference abstractPublished 27 Oct 2014

Preparing for U.S. market entry–strategy considerations in view of BPCIA and AIA

Authors: Renita S Rathinam

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

With clarity concerning the Biologics Price Competition & Innovation Act (BPCIA) of 2010 and imminent significant patent expirations on the horizon, the U.S. biologics market remains an increasingly prized landscape for industry players. We will revisit the BPCIA litigation framework and also examine critical paradigm shifts in U.S. patent law via the America Invents Act of 2011 that cannot be overlooked by biosimilar applicants or reference product sponsors. We will examine how these two pieces of legislation together present unique considerations for prosecution, collaboration and litigation strategies that should be implemented now.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Bioanalysis & Biomedicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioanalysis & Biomedicine
  • BylineArticles whose byline prints “Renita S Rathinam”